Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New lens implant helps presbyopia patients ditch reading glasses

NCT ID NCT03499821

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special lens implant (EVO+ Visian ICL) to improve near vision in 41 adults with presbyopia, an age-related condition that makes it hard to see up close. The lens is placed behind the iris and in front of the eye's natural lens. Six months after surgery, most eyes could see 20/40 or better at 40 cm without glasses. The results suggest this implant may be a helpful option for people who need reading glasses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EVO+ Visian ICL with Aspheric (EDOF) Optic (a lens implant)
What this could lead to
If successful, this lens could help people with presbyopia see up close without reading glasses.
What could go wrong
This is a small, completed study with only 41 participants. Long-term safety and effectiveness are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

41 people

The number who actually took part.

Started

Mar 2018

Finished

Jul 2019

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Must be able to read, understand and provide written informed consent, 2. Willing and able to comply with all treatment and follow-up study related procedures, 3. 40 - 60 years of age at time of surgery if require spherical lens powers from -0.50 D to -18.00 D, 4. 35 - 45 years of age at time of surgery if require a spherical lens power from 0.0 D to +3.00 D, 5. Preoperative refraction fully correctable with available lens powers, with ≤ 0.75 D preoperative refractive and residual cylinder, 6. \< 0.75 D spherical equivalent difference between cycloplegic and manifest refractions, 7. Stable correction (± 0.50 D) as determined by manifest refraction spherical equivalent (MRSE), 8. Best Corrected Distance Visual Acuity 20/20 or better in both eyes, 9. Requires +1.00 D to +2.50 D reading add, 10. Anterior chamber depth (ACD) ≥ 2.8 mm if require spherical lens powers from -0.50 D to -18.00 D, 11. ACD ≥ 3.0 mm if require spherical lens powers from 0.00 D to +3.00 D, 12. Anterior chamber angle ≥ Grade III, 13. Phakic in both eyes, 14. Current contact lens wearers need to demonstrate a stable refraction, (± 0.5 D), expressed as MRSE, on two consecutive examination dates with refractive stability determined by the following criteria: 1. contact lenses were not worn for at least 2 weeks (rigid and toric contact lenses) or 3 days (soft contact lenses) prior to the first refraction, 2. two refractions were performed at least 7 days apart. Exclusion Criteria: 1. Participation in a clinical trial within 30 days prior to entry into this study and/or during the period of study participation, 2. Previous intraocular or corneal surgery in either eye, including refractive surgery, 3. Progressive sight threatening disease or other previous or current ocular conditions, other than myopia in either eye, 4. Low/abnormal corneal endothelial cell density, 5. Amblyopia, 6. Presence of active or history of chronic inflammation in either eye, 7. Clinically significant irregular astigmatism in either eye, 8. Serious, acute, chronic or systemic, non-ophthalmic disease or illness that would increase the operative risk, confound the outcome(s) of the study or which may preclude study completion, 9. Use of topical steroids at time of implantation, 10. Systemic or topical medication, other than prescribed study medications that may confound the outcome or increase the risk to the subject, 11. Allergy to anesthetics or other postoperative medications required in this study, 12. Subject who is pregnant, plans to become pregnant, or is lactating during the course of the study, or has another condition associated with the fluctuation of hormones that could lead to refractive changes, 13. Subjects who present any emotional, physiologic, or anatomical condition which may preclude study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Presbyopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clínica Oftalmológica Gasteiz

    Vitoria-Gasteiz, 01005, Spain

  • IMO Instituto de Microcirugía Ocular

    Barcelona, 08035, Spain

  • Innova Ocular Begitek

    San Sebastián, 20012, Spain

  • Instituto Oftalmológico Fernández-Vega

    Oviedo, Principality of Asturias, 33012, Spain

  • Mediopolis

    Antwerp, B-2610, Belgium

  • Qvision-Hospital Vithas Virgen del Mar

    Almería, 04120, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.